Literature DB >> 9686699

Diverging evolution of anti-GAD and anti-IA-2 antibodies in long-standing diabetes mellitus as a function of age at onset: no association with complications.

L Hermitte1, C Atlan-Gepner, C Mattei, D Dufayet, M F Jannot, M A Christofilis, S Nervi, B Vialettes.   

Abstract

Glutamic acid decarboxylase autoantibodies (GAD-A) and tyrosine phosphatase IA-2 autoantibodies (IA2-A) were measured in sera of 50 recently diagnosed (<6 wk, 33% younger than 15 yr), 19 short-term (1 to 9 yr, 35% with onset age below 15 yr) and 89 long-standing diabetic patients (>10 yr, 57% with onset age below 15 yr). Complications were assessed by clinical examination, retinal angiographs and microalbuminuria measurement. Both prevalences and levels of GAD-A and IA2-A decreased with increasing duration of diabetes. However even in those with long duration diabetes, 15 to 63% of the sera were still positive for one or two antibodies. In the group with onset after the age of 15 yr, significantly higher prevalences and levels of GAD-A (but not IA2-A) was observed in comparison with the group with earlier onset. No association was found with any microvascular complications in any group. We conclude that GAD-A and IA2-A persist in some diabetic patients, despite a long duration. Persistence of GAD-A was greatest in those with postpubertal disease onset. We speculate that persistence of some beta-cells or specific environmental factors can sustain one autoimmune reaction especially in some postpubertal-onset diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9686699     DOI: 10.1002/(SICI)1096-9136(199807)15:7<586::AID-DIA624>3.0.CO;2-B

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  3 in total

1.  Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome.

Authors:  L Hermitte; N Martin-Moutot; J Boucraut; R Barone; C Atlan-Gepner; M Seagar; J Pouget; J P Kleisbauer; F Couraud; B Vialettes
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

2.  Diabetes mellitus among young adults in Sri Lanka--role of GAD antibodies in classification and treatment: the Sri Lanka Young Diabetes study.

Authors:  P Katulanda; B Shine; G W Katulanda; A Silva; E L Asfir; R Sheriff; N Somasundaram; A E Long; P J Bingley; M I McCarthy; A Clark; D R Matthews
Journal:  Diabetologia       Date:  2008-06-05       Impact factor: 10.122

3.  Interaction of onset and duration of diabetes on the percent of GAD and IA-2 antibody-positive subjects in the type 1 diabetes genetics consortium database.

Authors:  David M Tridgell; Charles Spiekerman; Richard S Wang; Carla J Greenbaum
Journal:  Diabetes Care       Date:  2011-02-17       Impact factor: 19.112

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.